Liraglutide in the treatment of type 2 diabetes mellitus: Clinical utility and patient perspectives

Patient Preference and Adherence

Volumn 4, Issue , 2010, Pages 61-68

  Edavalath, Mahamood ^a   Stephens, Jeffrey W ^a,b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

GLP 1 analogue; Glycemic control; Liraglutide; Obesity; Type 2 diabetes mellitus

Indexed keywords

EID: 77954597934     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108(12):1527-1532.
2. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288(20): 2579-2588.
3. Grill V, Bjorklund A. Overstimulation and beta-cell function. Diabetes. 2001;50 Suppl 1:S122-S124.
4. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-986.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012.
7. Keating GM. Exenatide. Drugs. 2005;65(12):1681-1692; discussion 1693-1685.
8. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26(10):2929-2940.
9. Joy SV, Rodgers PT, Scates AC. Incretin mimetics as emerging treatments for type 2 diabetes. Ann Pharmacother. 2005;39(1):110-118.
10. Holst JJ. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10(Suppl 3):14-21.
11. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 28 2009;373(9669):1083-1096.
12. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med. 2008;25(3):245-254.
13. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications. 2004;18(1):60-68.
14. Green J, Feinglos M. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract Suppl. 2007;154:3-11.
15. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43(9):1664-1669.
16. Gonzalez C, Beruto V, Keller G, Santoro S, Di Girolamo G. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. Expert Opin Investig Drugs. 2006;15(8):887-895.
17. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45(2):195-202.
18. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300-1304.
19. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993;38(4): 665-673.
20. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998;68(3):525-530.
21. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagonlike peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005;330(2):577-584.
22. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007;30(8):2032-2033.
23. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161-168.
24. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51(2):424-429.
25. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagonlike peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27(6):1335-1342.
26. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-278.
27. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
28. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
29. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MetMTZD). Diabetes Care. 2009;32(7):1224-1230.
30. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 metiSU): a randomised controlled trial. Diabetologia. 2009;52(10):2046-2055.
31. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
32. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616.
33. Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagonlike peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59-66.
34. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5): 834-838.
35. Bain SC, Stephens JW. Exenatide and pancreatitis: an update. Expert Opin Drug Saf. 2008;7(6):643-644.
36. Stephens JW, Bain SC. Safety and adverse effects associated with GLP-1 analogues. Expert Opin Drug Saf. 2007;6(4):417-422.
37. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083-1091.
38. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8): 559-569.
39. de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. 2007;56(2):438-443.
40. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes. 1996;104(2):106-110.
41. Ruvalcaba RH, Kletter GB. Abdominal lipohypertrophy caused by injections of growth hormone: a case report. Pediatrics. 1998; 102(2 Pt 1):408-410.
42. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005;22(8):1016-1023.
43. Frid ANM, Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D. Evaluation of patient reported outcomes in subjects with type 2 diabetes treated with the once-daily human GLP-1 analog liraglutide or glimepiride, both as add-on to metformin. American Diabetes Association's 68th Scientific Sessions; June 2008. Abstract 2080-PO.
44. Schmidt WE CJ, Hammer M, Zychma M, Buse JB. Patient-reported outcoes are superior in patients with type 2 diabetes treated with liraglutide as compared to exenatide, when added to metformin, sulfonylurea or both (LEAD-6). American Diabetes Association's 69th Scientific Sessions; June 2009. Abstract P-1880.